- Previous Close
15.73 - Open
16.40 - Bid 16.61 x 100
- Ask 17.13 x 100
- Day's Range
15.50 - 17.79 - 52 Week Range
1.37 - 38.50 - Volume
158,152 - Avg. Volume
1,270,156 - Market Cap (intraday)
89.089M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-2.30 - Earnings Date Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
www.monopartx.comRecent News: MNPR
View More
Performance Overview: MNPR
Trailing total returns as of 11/8/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNPR
View MoreValuation Measures
Market Cap
89.09M
Enterprise Value
81.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
14.63
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.44%
Return on Equity (ttm)
-102.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.12M
Diluted EPS (ttm)
-2.30
Balance Sheet and Cash Flow
Total Cash (mrq)
7.12M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.43M
Research Analysis: MNPR
View MoreCompany Insights: MNPR
MNPR does not have Company Insights